ReviewChirurgie (Heidelberg, Germany)2026
[Current concepts of total neoadjuvant therapy for rectal cancer].
Review in Chirurgie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- [Robotic-assisted rectal resection in rectal cancer: current evidence : A narrative review].Chirurgie (Heidelberg, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Total neoadjuvant therapy (TNT) refers to the addition of preoperative systemic therapy to preoperative radiotherapy (RT; 5 × 5 Gy) or chemoradiotherapy (ChRT) for rectal cancer. This can be administered either before RT/ChRT as induction therapy or after RT/ChRT as consolidation therapy. Randomized trials demonstrate improved tumor response (clinical or pathological complete remission) and a significant improvement in disease-free survival with TNT compared to neoadjuvant ChRT plus surgery with or without adjuvant chemotherapy. The updated S3 guidelines therefore recommend TNT, particularly for patients high-risk factors defined with magnetic resonance imaging (MRI, cT4, cN2, mrCRM+, EMVI+, lateral lymph node involvement). Following achievement of complete clinical remission after TNT organ-preserving (watch and wait) strategies are increasingly being favored and are being further optimized in ongoing clinical trials (e.g., ACO/ARO/AIO 18.1, JANUS, STELLAR II).
Indexed as
Identifiers
41665658What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.